With the help of continuous glucose monitoring, noteworthy progression has been possible to stabilize a high A1C level, which lower downs the risk of diabetic complications. Few other factors that contribute towards the market growth are technological modernization such as artificial pancreas, rising awareness among developed, developing and under developed economies, and rising pool of diabetic patients.

1. Continuous Glucose Monitoring Market (CGM Systems,
Application, Diabetic Type, and Adoption by Age Group) -
Current Trends, Size, Share, Industry Analysis, Competitive
Intelligence, Growth, Opportunities and Global Forecasts,
2012 - 2020
Published: Dec 2013
Pages: 92
Contact Us: +1 (617) 674-4143
Toll Free: +1 (855) 711-1555
Mail us: sales@reportsandintelligence.com
Detailed report at:
http://www.reportsandintelligence.com/continuous-glucose-
monitoring-cgm-market

2. Adoption of CGM- continuous glucose monitoring is a result of innovative diabetic management
devices. Loopholes that exist in the present glucose monitoring devices are efficiently
addressed by the pioneering CGM. With the help of continuous glucose monitoring, noteworthy
progression has been possible to stabilize a high A1C level, which lower downs the risk of
diabetic complications. Few other factors that contribute towards the market growth are
technological modernization such as artificial pancreas, rising awareness among developed,
developing and under developed economies, and rising pool of diabetic patients. Conversely,
factors such as stern authoritarian impositions, lack of reimbursement options, less accurate
results and high cost of the CGMs are impeding the growth of market. The report analyzed the
global continuous glucose monitors market to generate revenue of $568.5 million by 2020,
enrolling a CAGR of 14.8% during 2013-2020. This is due to technological advancements, to be
exact, the launch of artificial pancreas, expediency that the CGMs have over self-monitoring
glucose devices, and earlier detection of the hypo & hyperglycemic events by CGM.
In terms of application, the Global CGM market is divided into diagnostics, home settings, and
hospitals. The home settings segment would be the maximum revenue generator by 2020.
North America generates maximum revenue due to wider adoption of advanced technologies,
effective and well penetrated reimbursement policies, and rising cases of diabetics. Asia Pacific
would grow fastest due to rising pool of patients, per capita income and awareness among the
people.
Top market participants in the market are Medtronics, Animas Corporation, Dexcom, Omnipod
and Miraculins, Inc, Ypsomed AG, inlcuding others. The main tactics adopted by the companies
globally include collaborations, product launches and approvals. Collaborations in the regions
focus on distribution and commercialization of the devices.
KEY BENEFITS
 The report ranks the factors that are responsible to accelerate the market growth driven
by upper hand of CGM over Self monitoring glucose devices, approval for artificial
pancreas and many more
 Market is forecast for the period 2013 - 2020 with market revenues for 2 historic years
of 2010 and 2012
 Identification and analysis of key pockets of investment for CGM manufacturers
 Identification of challenges that must be addressed and overcome in the CGM market to
achieve fiscal success throughout the market
 Analysis of regulatory framework that regulates introduction of new CGM and puts light
on reimbursement scenario

3.  The report identifies and profiles key market participants that would drive innovation in
the CGM market
KEY MARKET SEGMENTS
GLOBAL MARKET, BY DEVICES
 Transmitter and Receivers
 Sensors
 Insulin Pump
GLOBAL MARKET, BY APPLICATION
 Diagnostics/Clinics
 Hospitals
 Home Settings
GLOBAL MARKET, BY AGE
 Children and Teens
 Youth
 Middle, Elderly and Aged
GLOBAL MARKET, BY GEOGRAPHY
 North America
 Europe
 Asia Pacific
 Row
KEY AUDIENCES
 Medical Devices Manufacturers
 Research Institutions
 Healthcare Institutions

4. Table of Content
CHAPTER 1 INTRODUCTION
1.1 ObjectivesandScope
1.2 ReportDescription
1.3 KeyBenefitsof the Report
1.4 ResearchMethodology
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 GLOBAL CONTINUOUS GLUCOSEMONITORS MARKET OVERVIEW
3.1 Healthcare ExpenditureonDiabetesWorldwide
3.2 Type-1DiabeticstoRemainKeyTargetfor CGM Market
3.2.1 Type-1Diabetes
3.2.1.1 Type-1DiabetesinYoungPeople
3.2.2 Type-2Diabetes
3.2.2.1 Type-2DiabetesinYoung People
3.2.3 Gestational Diabetes
3.2.4 OtherTypesof Diabetes
3.3 Market Intelligence
3.3.1 Top Factors ImpactingContinuousGlucose MonitorsMarket,2013-2020
3.3.1.1 Fda Approval of Artificial Pancreas
3.3.1.2 Convenience OfferedbyCGMOverSelf MonitoringGlucose Devices
3.3.1.3 Rise inIncidencesof DiabetesCasesGlobally
3.3.1.4 EarlierDetectionof the Hypoand HyperglycemicEventsbyCGM
3.3.1.5 Inadequate ReimbursementOptionsforCGMServe asBarriersfor itsAdoption
3.3.1.6 Accuracy and Cost Actsas a Hindrance inContinuingUse of CGM
3.3.1.7 Strict RegulatoryImpositions
3.3.1.8 Increase inAwarenessAmongDevelopingandUnderdevelopedEconomies
3.3.2 Top Three WinningStrategiesinthe ContinuousGlucose MonitorsMarket
3.3.2.1 Global Market PlayersPositioning
3.3.3 Top InvestmentPocketsinContinuousGlucose MonitorsMarket
3.3.3.1 ContinuousGlucose MonitorsMarket – by Device
3.3.3.2 ContinuousGlucose MonitorsMarket – by Applications
3.3.3.3 ContinuousGlucose MonitorsMarket – by Geography
3.4 Regulations
3.5 ReimbursementScenario
3.6 Market Dynamics
3.6.1 Drivers
3.6.1.1 Convenience OfferedbyCGMOverSelf MonitoringGlucose Devices
3.6.1.2 FDA Approval of Artificial PancreasEnablesClosingthe LoopandOvercomesthe Limitation
of CurrentDiabetesCare ManagementSystem
3.6.1.3 EarlierDetectionof the Hypoand HyperglycemicEventsbyCGM

5. 3.6.1.4 Rise in Incidencesof DiabetesCasesGlobally
3.6.1.5 Increase inAwarenessAmongthe PopulationinDevelopingandUnderdevelopedEconomies
3.6.2 Restraints
3.6.2.1 Strict RegulatoryImpositions
3.6.2.2 Inadequate ReimbursementOptionsforCGMServe asBarriersfor itsAdoption
3.6.2.3 Accuracy and Cost Actsas a Hindrance inContinuingUse of CGM
3.6.3 Market Opportunity
3.6.3.1 Growth inEmergingMarket
3.6.4 WinningStrategiesforMncsin EmergingMarkets
3.6.4.1 Tailoringthe ExistingProductstothe Local Market Needs
3.6.4.2 Adoptionof a Proactive HybridModel RatherThanDistributorManagement
3.6.4.3 Service RenderedMakesaDifference
3.6.4.4 PartnershipandAcquisitionKeytoEnhance Reachand Market Position
3.6.4.5 AdoptingAnEmerging-MarketAttitude
CHAPTER 4 CONTINUOUS GLUCOSEMONITORING SYSTEMS MARKET - BY
DEVICES
4.1 TransmitterandReceivers
4.2 Sensors
4.2.1 Market Trend
4.2.1.1 Non-InvasiveGlucose Sensors
4.2.1.2 SubcutaneousSensors(MinimallyInvasive Sensors)
4.2.1.3 Conventional Technology –Holter-TypeRetrospective Sensors
4.2.1.4 AdvancedTechnology –Real-Time Sensors
4.3 InsulinPump
4.3.1 Advantagesof InsulinPump
4.3.2 Disadvantagesof InsulinPump
4.3.3 Market Trend
CHAPTER 5 CONTINUOUS GLUCOSEMONITORING SYSTEM MARKET - BY
APPLICATION
5.1 Diagnostics/Clinics
5.2 Hospitals
5.3 Home Settings
5.4 Role of CGM in Private Practice
5.4.1 Team Members
5.4.2 Clinical Space
5.4.3 Scheduling
5.4.4 Keepingthe PatientsInformed
CHAPTER 6 CONTINUOUS GLUCOSEMONITORING SYSTEM MARKET – BY AGE
6.1 ChildrenandTeens
6.2 Youth
6.3 Middle ElderlyandAged

6. CHAPTER 7 CGM SYSTEMS MARKETBY GEOGRAPHY
7.1 NorthAmerica
7.2 Europe
7.2.1 Financial CostIncurred
7.3 AsiaPacific
7.4 Row
CHAPTER 8 COMPANY PROFILES
8.1 MedtronicInc.
8.1.1 CompanyOverview
8.1.2 CompanySnapshot
8.1.3 BusinessPerformance
8.1.4 StrategicMovesand Developments
8.1.4.1 Principal Strategies:ProductLaunch
8.1.4.2 SecondaryStrategies:Approval
8.1.4.3 OtherStrategies:Collaboration
8.1.5 SWOT Analysis&StrategicConclusions
8.2 DexcomInc.
8.2.1 CompanyOverview
8.2.2 CompanySnapshot
8.2.3 BusinessPerformance
8.2.4 StrategicMovesand Developments
8.2.4.1 Principal Strategies:Agreement/Partnership
8.2.4.2 SecondaryStrategies:Acquisition
8.2.5 SWOT Analysis&StrategicConclusions
8.3 NovoNordisk
8.3.1 CompanyProfile
8.3.2 CompanySnapshot
8.3.3 StrategicMovesand Developments
8.3.4 SWOT Analysis&StrategicConclusions
8.4 SpringHealthSolutionLtd
8.4.1 CompanyProfile
8.4.2 CompanySnapshot
8.4.3 StrategicMovesand Developments
8.4.3.1 Principal Strategies
8.4.4 SWOT Analysis&StrategicConclusions
8.5 Roche
8.5.1 CompanyProfile
8.5.2 CompanySnapshot
8.5.3 StrategicMovesand Developments
8.5.4 SWOT Analysis&StrategicConclusions
8.6 AnimasCorporation
8.6.1 CompanyProfile
8.6.2 CompanySnapshot
8.6.3 StrategicMovesand Developments
8.6.3.1 Principal Strategies

7. 8.6.4 SWOT Analysis&StrategicConclusions
8.7 YpsomedAG
8.7.1 CompanyProfile
8.7.2 CompanySnapshot
8.7.3 StrategicMovesand Developments
8.7.3.1 Principal Strategies:ProductExpansion
8.7.3.2 SecondaryStrategies:NewSubsidiary
8.7.3.3 OtherStrategies:AcquisitionandAgreements
8.7.4 SWOT Analysis&StrategicConclusions
8.8 InsuletCorporation
8.8.1 CompanyProfile
8.8.2 CompanySnapshot
8.8.3 StrategicMovesand Developments
8.8.3.1 Principal Strategies
8.8.4 SWOT Analysis&StrategicConclusions
LIST OF TABLES:
TABLE 1 FEATURES OF CURRENTLY AVAILABLESTAND-ALONECGMSYSTEMS (ASOF MARCH 2013)
TABLE 2 FEATURES OF CURRENTLY AVAILABLEINTEGRATEDCGM SYSTEMS (ASOF MARCH 2013)
TABLE 3 GLOBAL CONTINUOUSGLUCOSE MONITORINGSYSTEMS MARKET BY PRODUCT CATEGORY,
2011-2020, ($MILLION)
TABLE 4 GLOBAL CGM TRANSMITTERS ANDRECEIVERSMARKET BY GEOGRAPHY, 2011 - 2020,
($MILLION)
TABLE 5 GLOBAL CGM SENSORSMARKET BY GEOGRAPHY,2011 - 2020, ($MILLION)
TABLE 6 GLOBAL CGM INSULIN PUMP MARKET BY GEOGRAPHY, 2011 - 2020, ($MILLION)
TABLE 7 GLOBAL CGM MARKET BY APPLICATION SEGMENTS,2011 - 2020, ($MILLION)
TABLE 8 GLOBAL CGM MARKET IN DIAGNOSTICCENTERS,BY GEOGRAPHY, 2011 - 2020, ($THOUSAND)
TABLE 9 GLOBAL CGM MARKET IN HOSPITALS,BY GEOGRAPHY,2011 - 2020, ($THOUSAND)
TABLE 10 GLOBAL CGM MARKET IN HOME SETTINGS,BY GEOGRAPHY, 2011 - 2020, ($MILLION)
TABLE 11 GLOBAL CGM MARKET BY AGE, 2011 - 2020, ($MILLION)
TABLE 12 TYPE-1 DIABETES(0-14 YEARS),2013
TABLE 13 FACTORSIMPACTINGGEOGRAPHICAL REGIONSIN 2013 AND 2020
TABLE 14 GLOBAL CONTINUOUSGLUCOSE MONITORINGSYSTEMS BY GEOGRAPHY, 2011 - 2020,
($MILLION)
TABLE 15 THE PREVALENCEOF DIABETESIN THE ADULT POPULATION ACROSSTHE U.K. IN 2011
TABLE 16 PREVALENCEESTIMATES OF DIABETES (20-79 YEARS),2013, EUROPE
TABLE 17 PREVALENCEESTIMATES OF DIABETES,2013 & 2035
TABLE 18 PREVALENCEESTIMATES OF DIABETES (20-79 YEARS),2013, AFRICA REGION
TABLE 19 MEDTRONIC BUSINESS SNAPSHOT
TABLE 20 DEXCOM INC.BUSINESSSNAPSHOT
TABLE 21 NOVA NORDISKBUSINESSSNAPSHOT
TABLE 22 SPRINGHEALTH SOLUTION LTD BUSINESSSNAPSHOT
TABLE 23 ROCHE BUSINESSSNAPSHOT
TABLE 24 ANIMASCORPORATION BUSINESSSNAPSHOT

8. TABLE 25 YPSOMED AG BUSINESSSNAPSHOT
TABLE 26 INSULET CORPORATION BUSINESSSNAPSHOT
LIST OF FIGURES:
FIG. 1 GLOBAL HEALTH EXPENDITURE DUE TO DIABETES, BY GEOGRAPHY ($BILLION)
FIG. 2 GLOBAL HEALTH EXPENDITURE DUE TO DIABETES,20-79 YEARS ($BILLION)
FIG. 3 TREATMENT OF DIABETES,2011
FIG. 4 SIMILARITIES IN CAUSE OF PRE-DIABETESANDTYPE-2 DIABETES
FIG. 5 CGM ADOPTION BY DIFFERENTTYPES OFDIABETES PATIENTS
FIG. 6 PREVALENCEOF TYPE-1 DIABETES, BY GEOGRAPHY, (THOUSAND)
FIG. 7 GLOBAL PREVALENCEOFTYPE-2 DIABETES IN 2000 & ESTIMATED PREVALENCEIN 2030
FIG. 8 TOP FACTORSIMPACTINGCGM MARKET, 2013-2020
FIG. 9 TOP WINNINGSTRATEGY IN CGMMARKET, 2010 TO 2013 (SEPTEMBER)
FIG. 10 TOP WINNINGSTRATEGY IN CGM MARKET BY YEAR
FIG. 11 GLOBAL MARKET PLAYERS POSITIONING
FIG. 12 TOP INVESTMENTPOCKETSIN CGM DEVICE MARKETS
FIG. 13 TOP INVESTMENTPOCKETSIN CGM APPLICATION MARKETS
FIG. 14 TOP INVESTMENTPOCKETSIN CGM GEOGRAPHY MARKETS
FIG. 15 NUMBER OF INCIDENCESOFDIABETESGLOBALLY, BY GEOGRAPHY (2000, 2011 & 2030)
FIG. 16 GDP PER CAPITA IN EMERGING ECONOMIES
FIG. 17 EMERGING MARKET CAPITALIZATION STRATEGIES
FIG. 18 GLOBAL CGM MARKET AMONG CHILDREN,2011-2020, ($MILLION)
FIG. 19 GLOBAL CGM MARKET AMONG TEENS, 2011-2020, ($MILLION)
FIG. 20 GLOBAL CGM MARKET AMONG YOUTH, 2011-2020, ($MILLION)
FIG. 21 GLOBAL CGM MARKET AMONG MIDDLE ELDERLY, 2011-2020, ($MILLION)
FIG. 22 GLOBAL CGM MARKET AMONG AGED, 2011-2020, ($MILLION)
FIG. 23 NORTH AMERICA CGM MARKET, 2013-2020, ($MILLION)
FIG. 24 CASESOF DIABETES BY AGES IN NAC(1000S) (2013 E)
FIG. 25 EUROPE CGM MARKET, 2013-2020, ($MILLION)
FIG. 26 CASESOF DIABETES BY AGES IN EUROPE (1000S) (2013 E)
FIG. 27 ASIA PACIFICCGMMARKET, 2013-2020, ($MILLION)
FIG. 28 TOP 10 COUNTRIESWITH DIABETESINCIDENCES2013 AND2035
FIG. 29 ROW CGM MARKET, 2013-2020, ($MILLION)
FIG. 30 FINANCIALREVENUESBYBUSINESS UNITS (2013)
FIG. 31 FINANCIALREVENUESBYGEOGRAPHY (2013)
FIG. 32 FINANCIALREVENUES BYGEOGRAPHY (2012)

9. Contact Us:
Sona Padman
5320 SW MacadamAvenue,
Suite 100, Portland, OR97239
United States
Direct: +1 (617) 674-4143
Toll Free: +1 (855) 711-1555 (U.S. & Canada)
Fax: +1 (855) 550-5975
Email: sales@reportsandintelligence.com
Web: http://www.reportsandintelligence.com/